HealthcareOn the MoveCelgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's...Jun. 29, 2012 2:07 PM ETCelgene Corporation (CELG) StockCELGBy: David Yelle, SA News Editor Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's reiterated guidance following the Revlimid setback. Recommended For YouMore Trending NewsSee More »Related StocksSymbolLast Price% ChgCELG--Celgene CorporationTrending AnalysisTrending News